论文部分内容阅读
目的探讨倍他乐克联合起搏器治疗缓室率心力衰竭(心衰)患者的临床效果。方法 84例缓室率心衰患者,随机分成对照组及治疗组,每组42例。对照组给予常规治疗,治疗组在对照组基础上联合倍他乐克与起搏器治疗,比较两组患者的临床效果。结果治疗后治疗组患者的心力衰竭分级(NYHA)、左室射血分数(LVEF)、心输出量(CO)分别为(1.36±0.87)级、(0.46±0.14)%、(5.47±0.89)L/min,与治疗前的(2.95±0.53)级、(0.37±0.14)%、(4.74±0.73)L/min比较改善显著(P<0.05),但是左心室舒张期内径(LVDD)未见显著缩小,差异无统计学意义(P>0.05);而对照组患者的上述心功能指标与治疗前比较未见显著改善,差异均无统计学意义(P>0.05)。结论缓室率心衰患者应用倍他乐克联合起搏器治疗具有十分显著的临床效果,能够有效改善患者心功能,值得在临床上大力推广应用。
Objective To investigate the clinical effect of Betaloc combined with pacemaker in the treatment of patients with slow ventricular rate heart failure (HF). Methods Eighty-four patients with slow ventricular rate heart failure were randomly divided into control group and treatment group, 42 cases in each group. The control group was given routine treatment. The treatment group was treated with metoprolol and pacemaker on the basis of the control group, and the clinical effect was compared between the two groups. Results After treatment, the levels of NYHA, LVEF and CO in the treatment group were (1.36 ± 0.87), (0.46 ± 0.14)% and (5.47 ± 0.89), respectively L / min was significantly higher than that before treatment (2.95 ± 0.53), (0.37 ± 0.14)% and (4.74 ± 0.73) L / min, respectively, but the left ventricular diastolic diameter (P> 0.05). However, in the control group, there was no significant difference between the above cardiac function indexes and before treatment, the difference was not statistically significant (P> 0.05). Conclusions The application of metoprolol combined with pacemaker in patients with slow ventricular rate heart failure has a very significant clinical effect, which can effectively improve the cardiac function of patients and is worthy of great promotion and application in clinic.